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Cytomegalovirus (CMV) infection may be due to vertical 
transmission (congenital CMV), or it may be horizontally acquired. 
Systemic CMV infection is more widespread in developing 
countries and in communities with a lower socioeconomic status, 
and it represents the most significant viral cause of birth defects in 
industrialised countries.[1] CMV infection is typically subclinical 
and therefore asymptomatic in healthy individuals; however, it can 
be life-threatening for the immunocompromised; such as HIV-
positive patients, organ transplant recipients, and newborn babies.[2] 
Similar to other herpes viruses, CMV enters a latent state in which 
the virus is continually suppressed by cell-mediated immunity. 
CMV remains latent unless the patient suffers from a significant 
local or systemic immunodeficiency. Recurrent CMV infections 
are primarily associated with pneumonitis, colitis, encephalitis, and 
retinitis.[3] CMV retinitis is known to occur in immunocompromised 
adults, affecting up to 30% of HIV-positive adults and 5% of 
immunocompromised children.[4] CMV retinitis has been reported 
to be more likely in HIV-positive children with CD4 counts of 
<100 cells/µL, or CD4% <10%.[4] While it is reported that CMV 
retinitis presents less frequently in children than in adults, children 
may not report visual loss or associated symptoms, making detection 
more difficult in the paediatric population.[5]
According to our literature review, the prevalence of retinitis in 
children with probable systemic CMV infection in South Africa 
(SA) is still unknown. Permanent visual impairment in children with 
CMV retinitis may be prevented by timely diagnosis and treatment. 
This study aimed to determine the prevalence of CMV retinitis, and 
to assess the value of clinical and laboratory data in identifying risk 
factors for the development of the disease in the study population.
Methods
Ethical considerations
The study was approved by the Health Research Ethics Committee 
of Stellenbosch University (ref. no. N13/01/012). Internationally 
accepted ethical standards and guidelines were respected and patient 
confidentiality was protected.
Study population and sampling
A retrospective, cross-sectional study design was used. All children 
≤12 years admitted to Tygerberg Academic Hospital (TBH), with 
laboratory evidence of systemic CMV infection and who were 
referred for ophthalmological screening between 1 January 2009 
and 31 December 2013, were included in the study. TBH is a 
tertiary-level referral hospital in Cape Town, SA. Ophthalmological 
screening consisted of a thorough examination of the central and 
peripheral retina by means of indirect ophthalmoscopy through 
dilated pupils. The screening was performed by a registrar and/or 
consultant in the Department of Ophthalmology. Presumed CMV 
retinitis was diagnosed on the characteristic clinical appearance 
on ophthalmoscopy. All cases with presumed CMV retinitis were 
reviewed by a consultant ophthalmologist. The study cohort was 
screened to determine the prevalence of presumed CMV retinitis. 
All cases were evaluated to identify possible risk factors for 
the development of CMV retinitis. The immune status of all 
screened cases was evaluated and classified: nil immunodeficiency, 
prematurity, congenital immunodeficiency syndrome, perinatal 
vertical HIV exposure, HIV-positive organ transplantation, 
chemotherapy or other. Demographic, clinical and laboratory data 
of all children who underwent ophthalmological screening were 
collected and included the following: age, gender, T-lymphocyte 
subsets (including absolute CD4 and CD4/total lymphocyte count 
(CD4%)), site of systemic CMV infection, laboratory test type 
performed to detect CMV infection, and the nature of the specimen 
in which CMV was detected.
Laboratory analysis
Cases of probable systemic CMV infection were identified by CMV 
polymerase chain reaction (PCR), CMV pp65 antigenaemia test, CMV 
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viral culture, and CMV serology. If the qualitative PCR was positive, 
quantitative PCR was performed. Probable systemic CMV infection 
had an accompanying quantitative PCR that was higher than detectable 
limits. HIV was diagnosed by means of HIV PCR in children <18 
months of age, and by PCR or viral antibody tests for children >18 
months. CD subsets were analysed to determine the absolute CD4 
and CD4%. All white cells were counted and marked with CD3, CD4, 
and CD8 antibodies to determine the absolute CD count. CD4% was 
calculated by analysing the cells that exclusively contained the marker 
as a percentage of the total cells. Laboratory tests were performed by 
the National Health Laboratory Service. 
Data management and statistical analysis
IBM SPSS version 22 (IBM Corp., USA) was used to analyse the 
data. The data were summarised using mean and standard deviation 
in the case of normally distributed continuous data, and frequency 
tables and percentages in the case of categorical data. The prevalence 
of CMV retinitis in children with probable systemic CMV infection 
was calculated. Associations between the risk factors identified and 
the development of CMV retinitis were assessed using Fisher’s exact 
2-sided tests for categorical variables, and non-parametric Mann-
Whitney tests were used to compare non-normally distributed 
continuous variables between the groups. 
Results
Demographic and clinical data profile of the sample
A total of 164 cases with probable systemic CMV infection were 
referred for ophthalmological examination to assess the presence 
or absence of CMV retinitis. The median age was 3.1 months 
(range 1 day to 131.6 months), and the ratio of male to female 
was 1.1:1. The most common sites of presumed CMV infection 
were the respiratory system (n=122), hepatobiliary system (n=17), 
cardiovascular system (n=8), central nervous system (n=6), and 
gastrointestinal tract (n=3) (Table 1).
Underlying immunodeficiency
We identified 91 cases that were immunocompromised. Causes for 
immunosuppression were HIV infection (n=84), other immunodefi-
ciency (n=6), and chemotherapy for leukaemia (n=1) (Fig. 1).
HIV infection was diagnosed in 51.2% (n=84) of the screened 
cases. In our study population there was a definite trend towards 
association between HIV infection and the development of CMV 
retinitis (p=0.064). However, due to small numbers, this association 
could not be confirmed. Highly active antiretroviral therapy 
(HAART) was initiated 78 (93%) participants of the HIV-positive 
or HIV-exposed cases at the time of screening. A total of 55 (33.5%) 
premature infants were screened.
CMV retinitis group
CMV retinitis was diagnosed in 4.9% (n=8) of the cases screened. 
Age ranged from 3 months to 11 years and the male to female ratio 
was 1:4. The causes of immunosuppression in this group were HIV 
infection (n=7) and chemotherapy for leukaemia (n=1). All of the 
HIV-infected patients were on HAART. Two of the HIV-positive 
cases were also premature, but due to small numbers the significance 
of prematurity as a risk factor for CMV retinitis could not be proven. 
Laboratory data
Laboratory evidence of CMV infection was confirmed by the 
following tests: CMV PCR (n=136), CMV pp65 antigenaemia test 
(n=15), CMV viral culture (n=9), and CMV serology (n=4). All 
qualitative CMV PCR tests had an accompanying quantitative 
PCR higher than detectable limits. The HIV-positive group had 
a median absolute CD4 cell count of 598 cells/µL between HIV-
positive cases with and without CMV retinitis (p=0.032). The 
median CD4 cell count in those with CMV retinitis was 334 (range 
21 - 767), while in those without retinitis it was 622 cells/µL. 
CD4 as a percentage of the total lymphocyte count (CD4%) 
ranged between 2.1 and 64.3%, with a median of 16.6%. There was 
no significant difference between those with and without CMV 
retinitis in terms of CD4% (p=0.668). 
Discussion
There was an exponential increase in the number of paediatric cases 
with probable systemic CMV infection screened for retinitis at 
the Department of Ophthalmology, TBH, SA over a 5-year period 
(Fig. 2), with a resultant increased load on our already overburdened 
ophthalmology service.
In 2006, the estimated number of SA children infected with HIV 
was 293 000.[6] Due to the HIV pandemic, paediatric CMV infection 
is becoming more prevalent and CMV infection has been identified 
in up to 51% of HIV-positive children admitted to SA paediatric 
intensive care units.[7] Patients on immunosuppressive therapy or with 
immunodeficiency syndromes are predisposed to CMV infections.[5] 
The distinctive features of active CMV retinitis are: ‘a fulminant picture 
of retinal vasculitis and vascular sheathing with areas of yellow-white, 
full thickness, retinal necrosis producing retinal oedema associated 
Table 1. Site of presumed CMV infection (N=164)



















Fig. 1. Causes of underlying immunosuppression (n=91)
Fig. 2. CMV retinitis screenings at the Department of Ophthalmology, 
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with haemorrhage and hard exudates’.[8] The indolent variant is 
described as having less oedema and no haemorrhage or vascular 
sheathing.[8] In children, CMV retinitis is most often bilateral and 
can lead to a destructive retinitis of the posterior pole, resulting in 
permanent visual impairment.[8] Recent developments have led to 
rapid laboratory detection techniques for systemic CMV and treatment 
regimens for CMV infection have been improved and are more readily 
available.[9] Current treatment regimens include intravenous ganciclovir 
(6 mg/kg, 12 hourly) as the drug of choice, and oral valganciclovir 
and intravenous foscarnet as alternatives.[4] Although CMV-specific 
antiviral treatment may cause regression of retinitis, visual acuity may 
not improve due to macular or optic nerve involvement. Prolonged 
CMV antiviral treatment is needed to reduce recurrences of retinitis in 
children that remain immunocompromised.[10]
Several international studies have reported the incidence of CMV 
retinitis in HIV-positive cases: Rwanda 1.8%;[11] USA 2.3%[12]; and 
Canada 5%.[10] To our knowledge, this is the first study in SA to 
document the prevalence of presumed CMV retinitis in children with 
presumed systemic CMV infection. The gold standard for detecting 
congenital CMV in newborn children is viral isolation in the urine or 
saliva within the first 3 weeks of life, but serum PCR is reported to be 
equally sensitive and specific.[9] All the cases in our study population 
were diagnosed after the age of 3 weeks. We were therefore not able 
to distinguish congenital from acquired CMV infection.
Gender, prematurity, and site of systemic CMV infection were not 
significant risk factors for the development of retinitis in our paediatric 
sample. Screening for CMV retinitis in HIV-positive children with 
probable systemic CMV is imperative in South Africa. In our sample, 
7 of the 8 CMV retinitis cases identified were HIV-positive. Only one 
child in the HIV-negative group developed retinitis; this patient was on 
chemotherapy for the treatment of leukaemia. CD4 count and CD4% 
may prove to be valuable in identifying cases at high risk of developing 
CMV retinitis;[4] however, we could not confirm this association in our 
study. We would therefore recommend that caution be taken when 
using CD4 and/or CD4% as criteria for retinitis screening as some 
cases might remain undiagnosed. International guidelines reported 
that CD4 cell level is less predictive of risk for CMV disease in young 
infants with HIV, and CMV infection can occur in HIV-infected 
children with higher CD4 counts.[4] With appropriate protocols in 
place, children could be screened and diagnosed early, managed 
effectively, and possibly have more favourable visual outcomes. 
Conclusion
The prevalence of probable CMV retinitis in our study population 
was 4.9%. Other than HIV, we were not able to identify additional 
risk factors for CMV retinitis. Our results show that CD4 levels are 
possibly not a reliable guide to predict CMV retinitis. We recommend 
a multi-centre study to establish a robust screening protocol that may 
lessen the impact of the ever-increasing numbers of children at risk 
of CMV retinitis on ophthalmic services. 
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